ID

11991

Descrição

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01528865 Principal Investigator: Scott D Gitlin, MD

Link

https://clinicaltrials.gov/show/NCT01528865

Palavras-chave

  1. 30/08/2015 30/08/2015 -
Transferido a

30 de agosto de 2015

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Lymphoma NCT01528865

Eligibility Lymphoma NCT01528865

  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT01528865
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
Patients must have a histologically confirmed diagnosis of non-Hodgkin lymphoma (NHL)
Descrição

Patients must have a histologically confirmed diagnosis of non-Hodgkin lymphoma (NHL)

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0024305
UMLS CUI [2]
C0011900
Must have HERV-K(HML2) viral load of ≥1x103 using a gag primer reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Descrição

Must have HERV-K(HML2) viral load of ≥1x103 using a gag primer reverse transcriptase polymerase chain reaction (RT-PCR) assay

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1012096
UMLS CUI [2]
C0599161
Must have bi-dimensionally measurable disease.
Descrição

Must have bi-dimensionally measurable disease.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1513041
Patients with lymphomas that are felt to be incurable with any therapy and for whom there are no standard treatments that would be anticipated to be necessary or beneficial within the next 5 months. These patients can have received any amount of prior chemotherapy to enter this trial.
Descrição

Patients with lymphomas that are felt to be incurable with any therapy and for whom there are no standard treatments that would be anticipated to be necessary or beneficial within the next 5 months. These patients can have received any amount of prior chemotherapy to enter this trial.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0024299
UMLS CUI [2]
C0175969
All previous therapies must have been discontinued at least 4 weeks prior to initiation of the administration of this study's drugs.
Descrição

All previous therapies must have been discontinued at least 4 weeks prior to initiation of the administration of this study's drugs.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0677162
HIV negative by standard blood testing.
Descrição

HIV negative by standard blood testing.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0481430
Have an expected life expectancy of at least 5 months.
Descrição

Have an expected life expectancy of at least 5 months.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023671
Have an Eastern Cooperative Oncology Group (ECOG) performance scale status of 0 - 2l) Must have a serum creatinine <2.0 and creatinine clearance >30 ml/min/m2. Other organ dysfunction is eligible at the discretion of the PI.
Descrição

Have an Eastern Cooperative Oncology Group (ECOG) performance scale status of 0 - 2l) Must have a serum creatinine <2.0 and creatinine clearance >30 ml/min/m2. Other organ dysfunction is eligible at the discretion of the PI.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2]
C0600061
UMLS CUI [3]
C0812399
Agree to use a reliable method of birth control prior to drug initiation and for the duration of their study participation.
Descrição

Agree to use a reliable method of birth control prior to drug initiation and for the duration of their study participation.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
a) Have received chemotherapy or radiotherapy within 4 weeks
Descrição

chemotherapy; radiotherapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3665472
UMLS CUI [2]
C1522449
Have not recovered from the adverse effects or toxicities of lymphoma therapy most recently administered.
Descrição

Have not recovered from the adverse effects or toxicities of lymphoma therapy most recently administered.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0879626
UMLS CUI [2]
C0087111
Currently receiving any other investigational medication or therapy.
Descrição

Currently receiving any other investigational medication or therapy.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013230
Patients with a second malignancy that might interfere with interpretation of the results of this study.
Descrição

Patients with a second malignancy that might interfere with interpretation of the results of this study.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0085183
Patients with known allergic reaction to lamivudine or tenofovir disoproxil fumarate (DF).
Descrição

Patients with known allergic reaction to lamivudine or tenofovir disoproxil fumarate (DF).

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1527304
UMLS CUI [2]
C1099776
Patients on drugs that interfere with renal function or drugs that compete with tenofovir for active binding sites (i.e. intravenous cidofovir, acyclovir, ganciclovir, and valganciclovir).
Descrição

Patients on drugs that interfere with renal function or drugs that compete with tenofovir for active binding sites (i.e. intravenous cidofovir, acyclovir, ganciclovir, and valganciclovir).

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1547774
UMLS CUI [2]
C0232804
Uncontrolled concurrent illnesses, including, but not limited to, active/ongoing infection, symptomatic congestive heart failure, unstable angina pectoris.
Descrição

Uncontrolled concurrent illnesses, including, but not limited to, active/ongoing infection, symptomatic congestive heart failure, unstable angina pectoris.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0205420
UMLS CUI [2]
C0012634
Women who are pregnant, become pregnant, or are breast-feeding.
Descrição

Women who are pregnant, become pregnant, or are breast-feeding.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0549206
UMLS CUI [2]
C0006147
Standard blood tests that are positive for HIV infection
Descrição

Standard blood tests that are positive for HIV infection

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0745002

Similar models

Eligibility Lymphoma NCT01528865

  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT01528865
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
non-Hodgkin lymphoma (NHL); Diagnosis
Item
Patients must have a histologically confirmed diagnosis of non-Hodgkin lymphoma (NHL)
boolean
C0024305 (UMLS CUI [1])
C0011900 (UMLS CUI [2])
Human endogenous retrovirus K; Reverse Transcriptase Polymerase Chain Reaction
Item
Must have HERV-K(HML2) viral load of ≥1x103 using a gag primer reverse transcriptase polymerase chain reaction (RT-PCR) assay.
boolean
C1012096 (UMLS CUI [1])
C0599161 (UMLS CUI [2])
measurable disease
Item
Must have bi-dimensionally measurable disease.
boolean
C1513041 (UMLS CUI [1])
Lymphoma ;incurable diseases
Item
Patients with lymphomas that are felt to be incurable with any therapy and for whom there are no standard treatments that would be anticipated to be necessary or beneficial within the next 5 months. These patients can have received any amount of prior chemotherapy to enter this trial.
boolean
C0024299 (UMLS CUI [1])
C0175969 (UMLS CUI [2])
Recommend therapy discontinuation
Item
All previous therapies must have been discontinued at least 4 weeks prior to initiation of the administration of this study's drugs.
boolean
C0677162 (UMLS CUI [1])
HIV negative
Item
HIV negative by standard blood testing.
boolean
C0481430 (UMLS CUI [1])
life expectancy
Item
Have an expected life expectancy of at least 5 months.
boolean
C0023671 (UMLS CUI [1])
ECOG performance status; serum creatinine; creatinine clearance
Item
Have an Eastern Cooperative Oncology Group (ECOG) performance scale status of 0 - 2l) Must have a serum creatinine <2.0 and creatinine clearance >30 ml/min/m2. Other organ dysfunction is eligible at the discretion of the PI.
boolean
C1520224 (UMLS CUI [1])
C0600061 (UMLS CUI [2])
C0812399 (UMLS CUI [3])
birth control
Item
Agree to use a reliable method of birth control prior to drug initiation and for the duration of their study participation.
boolean
C0700589 (UMLS CUI [1])
Item Group
Exclusion Criteria
C0680251 (UMLS CUI-1)
chemotherapy; radiotherapy
Item
a) Have received chemotherapy or radiotherapy within 4 weeks
boolean
C3665472 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
Adverse effects; therapy
Item
Have not recovered from the adverse effects or toxicities of lymphoma therapy most recently administered.
boolean
C0879626 (UMLS CUI [1])
C0087111 (UMLS CUI [2])
Investigational New Drugs
Item
Currently receiving any other investigational medication or therapy.
boolean
C0013230 (UMLS CUI [1])
second malignancy
Item
Patients with a second malignancy that might interfere with interpretation of the results of this study.
boolean
C0085183 (UMLS CUI [1])
allergic reaction; Tenofovir disoproxil fumarate
Item
Patients with known allergic reaction to lamivudine or tenofovir disoproxil fumarate (DF).
boolean
C1527304 (UMLS CUI [1])
C1099776 (UMLS CUI [2])
Drug interference; renal function
Item
Patients on drugs that interfere with renal function or drugs that compete with tenofovir for active binding sites (i.e. intravenous cidofovir, acyclovir, ganciclovir, and valganciclovir).
boolean
C1547774 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
concurrent; Disease
Item
Uncontrolled concurrent illnesses, including, but not limited to, active/ongoing infection, symptomatic congestive heart failure, unstable angina pectoris.
boolean
C0205420 (UMLS CUI [1])
C0012634 (UMLS CUI [2])
pregnant; Breast Feeding
Item
Women who are pregnant, become pregnant, or are breast-feeding.
boolean
C0549206 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HIV positive
Item
Standard blood tests that are positive for HIV infection
boolean
C0745002 (UMLS CUI [1])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial